Compare Amylx Pharmaceuticals Inc (AMLX) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roblox Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Roblox Corp trades at $55.3 (market cap $39.63B). The key difference: Roblox Corp is far larger — about 20× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | RBLX | |
|---|---|---|
Market Cap | $1.98B | $39.63B |
Sector | Health | Media |
52-Week High | $18.70 | $141.56 |
52-Week Low | $7.64 | $41.30 |
Enterprise Value | $1.70B | $38.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Roblox (RBLX) trades at $55.35, down 1.9% on the day, amid a bullish technical signal and strong analyst support. The stock shows consistent revenue growth, with 2025 revenue reaching $4.89 billion, though it remains unprofitable with a net income margin of -20.69%. Recent earnings have beaten expectations, but the company faces headwinds from a securities class action lawsuit related to age-verification disclosures. Operating cash flow improved to $1.8 billion in 2025, signaling healthy core business operations despite ongoing losses.
The outlook for RBLX is mixed; robust user monetization and revenue growth present upside potential, supported by a consensus price target of $64.07. However, persistent losses, high valuation multiples like a P/B of 91.73, and legal risks weigh on investor confidence. The stock's trajectory hinges on achieving profitability and navigating regulatory scrutiny, making it a high-risk, growth-oriented play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
